Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2

Mol Pharmacol. 2006 Jul;70(1):101-11. doi: 10.1124/mol.105.019117. Epub 2006 Apr 12.

Abstract

2-Arachidonyl glycerol (2-AG) is an endogenous arachidonic acid derivative that binds cannabinoid receptors CB1 and CB2 and is hence termed an endocannabinoid. 2-AG also modulates a variety of immunological responses, including expression of the autocrine/paracrine T cell growth factor interleukin (IL)-2. The objective of the present studies was to determine the mechanism responsible for IL-2 suppression by 2-AG. Because of the labile properties of 2-AG, 2-AG ether, a nonhydrolyzable analog of 2-AG, was also used. Both 2-AG and 2-AG ether suppressed IL-2 expression independently of CB1 and CB2, as demonstrated in leukocytes derived from CB1/CB2-null mice. Moreover, we demonstrated that both 2-AG and 2-AG ether treatment activated peroxisome proliferator-activated receptor gamma (PPARgamma), as evidenced by forced differentiation of 3T3-L1 cells into adipocytes, induction of aP2 mRNA levels, and activation of a PPARgamma-specific luciferase reporter in transiently transfected 3T3-L1 cells. Consequently, the putative role of PPARgamma in IL-2 suppression by 2-AG and 2-AG ether was examined in Jurkat T cells. Concordant with PPARgamma involvement, the PPARgamma-specific antagonist 2-chloro-5-nitro-N-(4-pyridyl)-benzamide (T0070907) blocked 2-AG- and 2-AG ether-mediated IL-2 suppression. Likewise, 2-AG suppressed the transcriptional activity of two transcription factors crucial for IL-2 expression, nuclear factor of activated T cells and nuclear factor kappaB, in the absence but not in the presence of T0070907. 2-AG treatment also induced PPARgamma binding to a PPAR response element in activated Jurkat T cells. Together, the aforementioned studies identify PPARgamma as a novel intracellular target of 2-AG, which mediates the suppression of IL-2 by 2-AG in a manner that is independent of CB1 and/or CB2.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 3T3-L1 Cells
  • Adipogenesis / drug effects
  • Animals
  • Arachidonic Acids / chemistry
  • Arachidonic Acids / pharmacology*
  • Benzamides / pharmacology
  • Cells, Cultured
  • Endocannabinoids
  • Fatty Acid-Binding Proteins / genetics
  • Female
  • Gene Expression / drug effects
  • Glycerides / chemistry
  • Glycerides / pharmacology*
  • Humans
  • Interferon-gamma / genetics
  • Interleukin-2 / antagonists & inhibitors
  • Interleukin-2 / metabolism*
  • Interleukin-4 / genetics
  • Jurkat Cells
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NF-kappa B / metabolism
  • NFATC Transcription Factors / metabolism
  • PPAR gamma / genetics
  • PPAR gamma / metabolism*
  • Peroxisome Proliferator-Activated Receptors / genetics
  • Prostaglandin D2 / analogs & derivatives
  • Prostaglandin D2 / pharmacology
  • Protein Binding / drug effects
  • Pyridines / pharmacology
  • Receptor, Cannabinoid, CB1 / genetics
  • Receptor, Cannabinoid, CB1 / physiology*
  • Receptor, Cannabinoid, CB2 / genetics
  • Receptor, Cannabinoid, CB2 / physiology*
  • Response Elements / genetics
  • T-Lymphocytes / cytology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / metabolism
  • Thiazolidinediones / pharmacology

Substances

  • 15-deoxyprostaglandin J2
  • Arachidonic Acids
  • Benzamides
  • Endocannabinoids
  • Fatty Acid-Binding Proteins
  • Glycerides
  • Interleukin-2
  • NF-kappa B
  • NFATC Transcription Factors
  • PPAR gamma
  • Peroxisome Proliferator-Activated Receptors
  • Pyridines
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • T 0070907
  • Thiazolidinediones
  • Interleukin-4
  • Interferon-gamma
  • glyceryl 2-arachidonate
  • Prostaglandin D2
  • ciglitazone